Aurobindo Pharma's COVID-19 vaccine plan in limbo after partner fails to get EUA in Taiwan

Aurobindo Pharma on Tuesday said that its COVID-19 vaccine UB-612 programme hasn't progressed, as its partner Vaxxinity failed to secure the emergency use authorization (EUA) in Taiwan.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3qkUBY1
via IFTTT